Overview
Malignant mesothelioma of the pelvic peritoneum is a rare and aggressive malignancy arising from the serosal surfaces of the pelvic organs, often associated with asbestos exposure. Treatment approaches are challenging due to the diffuse nature of the disease and limited anatomical boundaries 1.Diagnosis
Imaging studies (CT, MRI) essential for initial assessment and staging 1.
Histopathological confirmation via peritoneal biopsy required for definitive diagnosis 1.
Biomarker analysis (e.g., mesothelin) may aid in diagnosis but is not definitive alone 1.Management
Surgical resection of the primary tumor mass followed by adjuvant therapies tailored to tumor type and extent 1.
Extracorporeal irradiation of autografts considered for pelvic reconstruction post-tumor resection, though associated with significant complications 1.
Adjuvant therapies (chemotherapy, radiation) customized based on individual patient factors and tumor characteristics 1.Special Populations
No specific data provided regarding management in pregnancy, pediatrics, elderly, or patients with comorbidities 1.Key Recommendations
Perform surgical resection of the primary pelvic peritoneal mesothelioma tumor mass followed by adjuvant therapy as indicated by tumor stage and type (Evidence: Expert opinion 1).
Consider extracorporeal irradiation of autografts for pelvic reconstruction post-resection, acknowledging high complication rates (Evidence: Weak 1).
Tailor adjuvant treatments (chemotherapy, radiation) based on individual patient and tumor characteristics, given limited specific guidance (Evidence: Expert opinion 1).References
1 Sys G, Uyttendaele D, Poffyn B, Verdonk R, Verstraete L. Extracorporeally irradiated autografts in pelvic reconstruction after malignant tumour resection. International orthopaedics 2002. link